{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T06:39:55Z","timestamp":1770791995774,"version":"3.50.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-13814-9","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T06:20:51Z","timestamp":1741760451000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparison analysis of ICIs and chemotherapy combined with or without lenvatinib as first-line treatment of unresectable intrahepatic cholangiocarcinoma"],"prefix":"10.1186","volume":"25","author":[{"given":"Miao","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"issue":"1","key":"13814_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7\u201333.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"13814_CR2","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1634\/theoncologist.2015-0446","volume":"21","author":"SK Saha","year":"2016","unstructured":"Saha SK, Zhu AX, Fuchs CS, Brooks GA. Forty-Year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise. Oncologist. 2016;21(5):594\u20139.","journal-title":"Oncologist"},{"issue":"2","key":"13814_CR3","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3322\/caac.21759","volume":"73","author":"D Moris","year":"2023","unstructured":"Moris D, Palta M, Kim C, Allen PJ, Morse MA, Lidsky ME. Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians. CA Cancer J Clin. 2023;73(2):198\u2013222.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"13814_CR4","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.3892\/or.2013.2290","volume":"29","author":"R Dhanasekaran","year":"2013","unstructured":"Dhanasekaran R, Hemming AW, Zendejas I, George T, Nelson DR, Soldevila-Pico C, Firpi RJ, Morelli G, Clark V, Cabrera R. Treatment outcomes and prognostic factors of intrahepatic cholangiocarcinoma. Oncol Rep. 2013;29(4):1259\u201367.","journal-title":"Oncol Rep"},{"issue":"14","key":"13814_CR5","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273\u201381.","journal-title":"N Engl J Med"},{"issue":"5","key":"13814_CR6","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/S1470-2045(24)00082-2","volume":"25","author":"HA Burris","year":"2024","unstructured":"Burris HA 3rd, Okusaka T, Vogel A, Lee MA, Takahashi H, Breder V, Blanc JF, Li J, Bachini M, \u017botkiewicz M, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2024;25(5):626\u201335.","journal-title":"Lancet Oncol"},{"issue":"10391","key":"13814_CR7","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, Yau T, Kl\u00fcmpen HJ, Chan SL, Ozaka M, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10391):1853\u201365.","journal-title":"Lancet"},{"issue":"2","key":"13814_CR8","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S1470-2045(11)70301-1","volume":"13","author":"J Lee","year":"2012","unstructured":"Lee J, Park SH, Chang HM, Kim JS, Choi HJ, Lee MA, Jang JS, Jeung HC, Kang JH, Lee HW, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2012;13(2):181\u20138.","journal-title":"Lancet Oncol"},{"issue":"4","key":"13814_CR9","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1002\/hep.26890","volume":"59","author":"Y Arai","year":"2014","unstructured":"Arai Y, Totoki Y, Hosoda F, Shirota T, Hama N, Nakamura H, Ojima H, Furuta K, Shimada K, Okusaka T, et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology. 2014;59(4):1427\u201334.","journal-title":"Hepatology"},{"issue":"9","key":"13814_CR10","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","volume":"21","author":"V Subbiah","year":"2020","unstructured":"Subbiah V, Lassen U, \u00c9lez E, Italiano A, Curigliano G, Javle M, de Braud F, Prager GW, Greil R, Stein A, et al. Dabrafenib plus Trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol. 2020;21(9):1234\u201343.","journal-title":"Lancet Oncol"},{"issue":"4","key":"13814_CR11","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/ijc.26094","volume":"130","author":"AC Ziogas","year":"2012","unstructured":"Ziogas AC, Gavalas NG, Tsiatas M, Tsitsilonis O, Politi E, Terpos E, Rodolakis A, Vlahos G, Thomakos N, Haidopoulos D, et al. VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor type 2. Int J Cancer. 2012;130(4):857\u201364.","journal-title":"Int J Cancer"},{"issue":"1","key":"13814_CR12","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41392-023-01317-7","volume":"8","author":"GM Shi","year":"2023","unstructured":"Shi GM, Huang XY, Wu D, Sun HC, Liang F, Ji Y, Chen Y, Yang GH, Lu JC, Meng XL, et al. Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study. Signal Transduct Target Ther. 2023;8(1):106.","journal-title":"Signal Transduct Target Ther"},{"issue":"9","key":"13814_CR13","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1007\/s00262-023-03466-8","volume":"72","author":"C Zhu","year":"2023","unstructured":"Zhu C, Li H, Yang X, Wang S, Wang Y, Zhang N, Wang Y, Xue J, Zhang L, Ning C, et al. Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study. Cancer Immunol Immunother. 2023;72(9):2949\u201360.","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"13814_CR14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"5","key":"13814_CR15","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1159\/000494844","volume":"8","author":"A Hiraoka","year":"2019","unstructured":"Hiraoka A, Kumada T, Michitaka K, Kudo M. Newly proposed ALBI grade and ALBI-T score as tools for assessment of hepatic function and prognosis in hepatocellular carcinoma patients. Liver Cancer. 2019;8(5):312\u201325.","journal-title":"Liver Cancer"},{"issue":"1","key":"13814_CR16","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1097\/SLA.0000000000002064","volume":"267","author":"K Sasaki","year":"2018","unstructured":"Sasaki K, Morioka D, Conci S, Margonis GA, Sawada Y, Ruzzenente A, Kumamoto T, Iacono C, Andreatos N, Guglielmi A, et al. The tumor burden score: A new Metro-ticket prognostic tool for colorectal liver metastases based on tumor size and number of tumors. Ann Surg. 2018;267(1):132\u201341.","journal-title":"Ann Surg"},{"issue":"2","key":"13814_CR17","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","volume":"15","author":"SI Ilyas","year":"2018","unstructured":"Ilyas SI, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018;15(2):95\u2013111.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"13814_CR18","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.path.2022.05.006","volume":"15","author":"NJ Param","year":"2022","unstructured":"Param NJ, Bramel ER, Sia D. The molecular pathogenesis and targeted therapies for cholangiocarcinoma. Surg Pathol Clin. 2022;15(3):529\u201339.","journal-title":"Surg Pathol Clin"},{"issue":"7528","key":"13814_CR19","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature14011","volume":"515","author":"RS Herbst","year":"2014","unstructured":"Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563\u20137.","journal-title":"Nature"},{"key":"13814_CR20","doi-asserted-by":"publisher","first-page":"12624","DOI":"10.1038\/ncomms12624","volume":"7","author":"JJ Wallin","year":"2016","unstructured":"Wallin JJ, Bendell JC, Funke R, Sznol M, Korski K, Jones S, Hernandez G, Mier J, He X, Hodi FS, et al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat Commun. 2016;7:12624.","journal-title":"Nat Commun"},{"issue":"7","key":"13814_CR21","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamaoncol.2019.0250","volume":"5","author":"M He","year":"2019","unstructured":"He M, Li Q, Zou R, Shen J, Fang W, Tan G, Zhou Y, Wu X, Xu L, Wei W, et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs Sorafenib alone for hepatocellular carcinoma with portal vein invasion: A randomized clinical trial. JAMA Oncol. 2019;5(7):953\u201360.","journal-title":"JAMA Oncol"},{"key":"13814_CR22","doi-asserted-by":"crossref","unstructured":"Chen X, Wu X, Wu H, Gu Y, Shao Y, Shao Q, Zhu F, Li X, Qian X, Hu J et al. Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial. J Immunother Cancer 2020;8(2).","DOI":"10.1136\/jitc-2020-001240"},{"key":"13814_CR23","doi-asserted-by":"publisher","first-page":"1204486","DOI":"10.3389\/fonc.2023.1204486","volume":"13","author":"JX Huang","year":"2023","unstructured":"Huang JX, Liu B, Li Y, Li X, Ding LJ, Wang NY. Comparison analysis of PD-1\/PD-L1 inhibitors plus lenvatinib or gemcitabine\/cisplatin as first-line treatment for patients with advanced intrahepatic cholangiocarcinoma. Front Oncol. 2023;13:1204486.","journal-title":"Front Oncol"},{"key":"13814_CR24","doi-asserted-by":"publisher","first-page":"785535","DOI":"10.3389\/fonc.2022.785535","volume":"12","author":"Y Wang","year":"2022","unstructured":"Wang Y, Yang X, Wang D, Yang X, Wang Y, Long J, Zhou J, Lu Z, Mao Y, Sang X, et al. Lenvatinib beyond First-Line therapy in patients with advanced biliary tract carcinoma. Front Oncol. 2022;12:785535.","journal-title":"Front Oncol"},{"key":"13814_CR25","doi-asserted-by":"publisher","first-page":"1109292","DOI":"10.3389\/fimmu.2023.1109292","volume":"14","author":"C Zhu","year":"2023","unstructured":"Zhu C, Xue J, Wang Y, Wang S, Zhang N, Wang Y, Zhang L, Yang X, Long J, Yang X, et al. Efficacy and safety of lenvatinib combined with PD-1\/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer. Front Immunol. 2023;14:1109292.","journal-title":"Front Immunol"},{"issue":"10","key":"13814_CR26","doi-asserted-by":"publisher","first-page":"100557","DOI":"10.1016\/j.jhepr.2022.100557","volume":"4","author":"H Toyoda","year":"2022","unstructured":"Toyoda H, Johnson PJ. The ALBI score: from liver function in patients with HCC to a general measure of liver function. JHEP Rep. 2022;4(10):100557.","journal-title":"JHEP Rep"},{"issue":"2","key":"13814_CR27","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/jso.25486","volume":"120","author":"DI Tsilimigras","year":"2019","unstructured":"Tsilimigras DI, Hyer JM, Moris D, Sahara K, Bagante F, Guglielmi A, Aldrighetti L, Alexandrescu S, Marques HP, Shen F, et al. Prognostic utility of albumin-bilirubin grade for short- and long-term outcomes following hepatic resection for intrahepatic cholangiocarcinoma: A multi-institutional analysis of 706 patients. J Surg Oncol. 2019;120(2):206\u201313.","journal-title":"J Surg Oncol"},{"issue":"1150","key":"13814_CR28","doi-asserted-by":"publisher","first-page":"20230079","DOI":"10.1259\/bjr.20230079","volume":"96","author":"Z Ning","year":"2023","unstructured":"Ning Z, Xie L, Yan X, Hua Y, Shi W, Lin J, Xu L, Meng Z. Transarterial chemoembolization plus lenvatinib with or without a PD-1 inhibitor for advanced and metastatic intrahepatic cholangiocarcinoma: a retrospective real-world study. Br J Radiol. 2023;96(1150):20230079.","journal-title":"Br J Radiol"},{"issue":"11","key":"13814_CR29","doi-asserted-by":"publisher","first-page":"3717","DOI":"10.1007\/s00262-023-03523-2","volume":"72","author":"J Chao","year":"2023","unstructured":"Chao J, Wang S, Wang H, Zhang N, Wang Y, Yang X, Zhu C, Ning C, Zhang X, Xue J, et al. Real-world cohort study of PD-1 Blockade plus lenvatinib for advanced intrahepatic cholangiocarcinoma: effectiveness, safety, and biomarker analysis. Cancer Immunol Immunother. 2023;72(11):3717\u201326.","journal-title":"Cancer Immunol Immunother"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13814-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-13814-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13814-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T10:45:50Z","timestamp":1741862750000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-13814-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,12]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13814"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-13814-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,12]]},"assertion":[{"value":"11 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was in compliance with the ethical standards of Declaration of Helsinki, and was approved by the Institutional Ethics Committees of the Zhongshan Hospital, Fudan University. Informed consent was obtained from all the patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"439"}}